Study #2024-0474
Phase Ib study of CBP-1019 in combination with FOLFOX +/- bevacizumab, pembrolizumab, or enzalutamide for metastatic solid tumors of epithelial origin
MD Anderson Study Status
Enrolling
Treatment Agent
CBP-1019, Oxaliplatin, Leucovorin, 5-FLUOROURACIL, Bevacizumab, Pembrolizumab, Enzalutamide
Description
An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor
Study phase:
Phase I
Physician name:
Siqing Fu
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-997-2081
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.